secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2026-08-12T20:12:27+00:00
Accession:  0001628280-26-056198
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene Q2 2026: Cema-Cel MRD clearance 58.3% vs 16.7%; FDA grants RMAT and Fast Track
--------------------------------------------------------------------------------

- Cema-Cel ALPHA3 interim analysis: 58.3% (7/12) MRD-negative vs 16.7% (2/12) observation; 41.6% absolute difference.
- FDA granted RMAT and Fast Track designations for cema-cel as 1L LBCL consolidation after interim futility review.
- Site activations accelerated: >80 sites six months early; ~100 sites expected by year-end 2026; enrollment complete by YE2027.
- Q2 2026 net loss $42.7M ($0.13/share); cash $423.6M, runway into 2029; 2026 GAAP opex ~$225M.
- ALLO-329 RESOLUTION trial enrolling briskly; clinical data update expected Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000162828026056198/0001628280-26-056198-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000162828026056198/allo-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-056198

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer